BCL6: A Novel Target for Therapy of Ph+ B Cell Acute Lymphoblastic Leukemia  by Van Etten, Richard A.
Cancer Cell
PreviewsBCL6: A Novel Target for Therapy
of Ph+ B Cell Acute Lymphoblastic LeukemiaRichard A. Van Etten1,*
1Molecular Oncology Research Institute and Division of Hematology/Oncology, Tufts Medical Center, Boston, MA 02111, USA
*Correspondence: rvanetten@tuftsmedicalcenter.org
DOI 10.1016/j.ccr.2011.06.021
BCL6 is a zinc-finger transcriptional repressor known for its oncogenic role in B cell lymphoma. In a recent
issue ofNature, Duy et al. describe a novel role for BCL6 at the center of a transcriptional network in Ph+ acute
lymphoblastic leukemia cells that modulates their leukemogenicity and response to kinase inhibitors.The Philadelphia chromosome-positive
(Ph+) leukemias, chronicmyeloid leukemia
(CML), and Ph+ B cell acute lymphoblastic
leukemia (B-ALL) are prevalent blood
cancers that comprise about a quarter of
all leukemias in adults. The product of
the Ph chromosome, BCR-ABL1, is a dys-
regulated protein-tyrosine kinase that is
thedirect causeof both formsof leukemia,
as ectopic expression of BCR-ABL1 in the
relevant bonemarrow target cells leads to
phenotypically identical neoplasms in
mice (Hu et al., 2006). In CML patients in
the chronic phase of their disease, treat-
ment with any one of the three BCR-
ABL1 tyrosine kinase inhibitors (TKIs)
approved by the United States Food and
Drug Administration (imatinib, dasatinib,
or nilotinib) is remarkably effective, with
the great majority of patients achieving
sustained cytogenetic remissions. Unfor-
tunately, the outcome of TKI therapy in
Ph+ B-ALL is not nearly as favorable,
with most patients relapsing quickly after
transient decreases in the burden of their
leukemia (Druker et al., 2001). Although
TKIs are being incorporated into chemo-
therapy regimens for treatment of Ph+
B-ALL, the best chance for long-term
survival for such patients is to undergo
allogeneic hematopoietic stem cell trans-
plantation, a risky and costly procedure.
The mechanism of selective killing of
BCR-ABL1-expressing leukemic cells by
ABL1-specific TKIs is not completely
understood, but upregulation of proapop-
totic pathways may contribute, as leuke-
mias induced by BCR-ABL1 in bone
marrow cells from mice lacking p53
(Wendel et al., 2006) or Bim (Kuroda
et al., 2006) are relatively resistant to ima-
tinib. The reasons for relapse of Ph+B-ALL
following TKI therapy are also murky.
While some recurrences can be ascribedto amplification of the BCR-ABL1 fusion
gene or to BCR-ABL1 kinase domain
mutations that render the enzyme resis-
tant to the TKI (Gorre et al., 2001), the
majority of treatment failures are blamed
on the inability of the drug to eliminate
the so-called leukemia stem cells, defined
rigorously as clonogenic leukemic cells
capable of recapitulating the disease
upon transplantation. Studies in synge-
neic mouse models (Hu et al., 2006)
and from xenotransplantation of human
B-ALL into immunodeficient mouse recip-
ients (Castor et al., 2005) indicate that
these leukemia-initiating cells have the
phenotype of early B-lymphoid progeni-
tors. Hence, there is currently great
interest in identifying molecular strategies
to accentuate the killing of leukemic stem
cells by TKIs in patients with Ph+ B-ALL,
with the aim of eliminating residual
disease and increasing the chance of
cure.
In a study published in a recent issue of
Nature, Markus Mu¨schen and colleagues,
via an elegant and sophisticated set of
experiments, implicate BCL6 as a key
element of a transcriptional network in
BCR-ABL1-expressing B-ALL cells that
controls the cell cycle and apoptotic
responses to TKI treatment (Duy et al.,
2011). Microarray analysis of changes in
geneexpression triggeredbyTKI treatment
of B-ALL cells expressing BCR-ABL1 or
several other dysregulated TKs identified
BCL6 as the most highly TKI-induced
gene. Biochemical studies demonstrated
that BCL6 expression is normally inhibited
in BCR-ABL1-expressing B-ALL cells
through direct repression by activated
STAT5 and via AKT-mediated inhibition of
the BCL6 activator FoxO4. The transcrip-
tional targets of BCL6 in TKI-treated Ph+
B-ALL cells, identified through ChIP onCancer Cchip and comparative gene expression
analyses, include p53, ARF, and the cell
cycle regulators p21 and p27. While
BCR-ABL1 could readily immortalize
B-lymphoid progenitors from Bcl6+/+ and
Bcl6/mice in vitro, theBCR-ABL1-trans-
formed Bcl6/ B-lymphoblasts were
profoundly impaired in their ability to induce
fatal B-ALL in immunodeficient mice and
were unable to establish leukemia in
secondary transplant recipients, sugges-
tive of a defect in the self-renewal of
Bcl6/ leukemic stem cells. When chal-
lenged with imatinib, Bcl6/ BCR-ABL1+
B-ALLcellswerenearly10-foldmoresensi-
tive than their Bcl6+/+ counterparts and
exhibited an altered cellular response to
BCR-ABL1 inhibition with increased p53
expression and apoptosis, whereas
Bcl6+/+ lymphoblastshadamorerestrained
induction of p53 and exited the cell cycle to
become quiescent. These findings were
reproduced in primary human Ph+ B-ALL
samples transduced with a dominant-
negative BCL6 mutant. Together, these
results suggest a model wherein tonic
repression of BCL6 increases the
leukemogenicity of BCR-ABL1-trans-
formed B-lymphoid progenitors, whereas
induction of BCL6 tends to counteract
TKI-induced apoptosis through repression
of p53 and ARF (Figure 1).
Howmight these new findings be trans-
lated to the clinic? In drug development,
targeting transcription factors (at least
those that lack natural ligands such as
nuclear hormone receptors) has proven
notoriously difficult. In this work, the
authors turned to a novel peptidomimetic
inhibitor of BCL6, RI-BPI, which binds to
BCL6 and blocks its ability to recruit core-
pressor proteins. RI-BPI increased the
sensitivity of BCR-ABL1+ B-ALL cells to
imatinib to a similar extent as BCL6ell 20, July 12, 2011 ª2011 Elsevier Inc. 3
Figure 1. BCL6 Attenuates the Response to BCR-ABL1 Kinase Inhibition in Ph+ B-ALL Cells
(A) In untreated Ph+ lymphoid leukemia cells, BCL6 gene expression is inhibited by direct repression via
activated STAT5 and through inhibition of the BCL6 activator FOXO4 via AKT.
(B) Upon inhibition of BCR-ABL1 kinase activity by imatinib treatment, BCR-ABL1 signaling is reversed,
but induction of BCL6 expression through activated FOXO4 leads to repression of p53 and p27 genes,
blunting the apoptotic response.
(C) When the BCL6 inhibitor RI-BPI is added to imatinib treatment, BCL6 target genes including p53 are
induced, accentuating the antileukemic effect of TKIs.
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dependent onp53. Togetherwith imatinib,
RI-BPI effectively suppressed the emer-4 Cancer Cell 20, July 12, 2011 ª2011 Elsevigenceof resistant Ph+B-ALL in vitro, while
the combination of nilotinib (amore potent
analog of imatinib) and RI-BPI was well-er Inc.tolerated and cured the majority of mice
bearing Ph+ B-ALL xenografts.
These exciting findings suggest that
simultaneously targeting BCR-ABL1 and
BCL6 is a promising strategy for prevent-
ing TKI resistance and relapse in patients
with Ph+ B-ALL (Figure 1). Several
aspects of the study will require clarifica-
tion. The experiments do not clearly
distinguish between the effects of BCL6
loss or inhibition on the bulk of BCR-
ABL1+ B-ALL cells versus the more prim-
itive and refractory leukemic stem cells.
Moreover, loss of ARF is a frequent event
in the progression of BCR-ABL1-trans-
formed B-lymphoid progenitors (Williams
et al., 2006) and in human Ph+ B-ALL; it is
unclear how this might affect the
response to RI-BPI. The role of BCL6
at the interface between BCR-ABL1
signaling and response to TKIs argues
that the use of other signal transduction
inhibitor drugs in Ph+ leukemia should
be approached with caution, as inhibitors
of the phosphatidylinositol 3-kinase/AKT
pathway might induce BCL6 and
diminish the effectiveness of TKI therapy.
Finally, the development of clinical TKI
resistance based on acquired ABL1
kinase domain mutations, particularly
the troublesome gatekeeper mutation
T315I, would be expected to thwart the
efficacy of dual nilotinib/RI-BPI treat-
ment. In this regard, testing RI-BPI in
combination with third-generation BCR-
ABL1 TKIs capable of inhibiting the
T315I mutant (Chan et al., 2011; O’Hare
et al., 2009) is warranted.REFERENCES
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Massively parallel sequencing enables the sequencing of whole genomes, exomes, and transcriptomes from
many tumor samples. Thus, it now is possible to comprehensively identify somatic mutations, including
single base changes, deletions, insertions, and genomic rearrangements. Early results for hematopoietic
tumors show great promise, but many questions remain to be answered.Improved methods for sequencing the
human genome at an increasingly lower
cost are now being applied to all kinds
of tumors (Lander, 2011). A recent paper
in Nature (Puente et al., 2011) offers
a glimpse of the power of integrating
genomic technologies, including global
sequence analysis, in B cell chronic
lymphocytic leukemia (CLL). Genomic
analysis started from an in-depth analysis
of four patients representing the two
major molecular subtypes of CLL: two
with and two without somatic hypermuta-
tion of the immunoglobulin heavy chain
variable region (IGHV). Paired advanced
tumor and normal blood cells isolated
before and after treatment, respectively,
were studied using multiple independent
technologies: whole genome sequencing
(WGS); mate pair sequencing of 2.5 kb
DNA fragments for efficient detection of
DNA rearrangements; and chip analyses
for single nucleotide polymorphisms
(SNPs), DNA copy number, and RNA
expression. This allowed the authors to
determine that the sequencing identified
99.4% of the heterozygous SNPs. Impor-
tantly, for a subset of the putative somatic
mutations, they were able to validate 96%
by Sanger sequencing. They foundapproximately 1000 somatic substitutions
per CLL genome. The pattern of base
changes and dinucleotide context
differed for the IGHV-mutated and IGHV-
unmutated tumors. The authors sug-
gested that the higher frequency of A > T
and C > G transversions in the IGHV-
mutated cases was consistent with their
introduction by the error prone-poly-
merase h during somatic hypermutation
in immunoglobulin genes. Altogether,
they identified changes in the protein-
coding region of 45 genes in the four
tumors, including 41 nonsynonymous
single base substitutions and 5 inser-
tions/deletions (indels). Typically, CLL
have only a limited number of genomic re-
arrangements. The comprehensive mate
pair analyses enabled the authors to iden-
tify and characterize ten large genomic
alterations, six of which—including large
13q14 deletions in three tumors—have
been reported previously in CLL.
Focusing on the 26mutated, expressed
genes, Puente et al. (2011) then extended
these findings to a cohort of 169 CLL pa-
tients. Using a clever pooled-sequencing
strategy, they determined that other CLL
tumors had mutations, suggesting identi-
fication of four driver genes: NOTCH1,12.2%; MYD88, 2.9%; XPO, 2.4%; and
KLHL6, 1.8%. The nonsynonymous to
synonymous mutation ratio in the remain-
ing 22 expressed genes and the 19 unex-
pressed genes were 2.83 and 2.71,
respectively, consistent with the lack of
selection expected if most are passenger
genes (Chapman et al., 2011).
Of the NOTCH1 mutations, which
occurred in 20% of IGHV-unmutated
and 7% of IGHV-mutated CLL, 29/31
were the P2515Rfs*4. Thismutation previ-
ously had been identified in lymphoid
malignancies, including T cell acute
lymphoblastic leukemia and B-CLL. The
P2515Rfs*4 mutation and the other two
NOTCH 1 mutations all generate prema-
ture stop codons predicted to result in
truncated proteins lacking the destabiliz-
ing PEST domain. The authors confirmed
that leukemias carrying the NOTCH1
P2515Rfs*4 mutation expressed higher
levels of truncated NOTCH1, together
with higher levels of NOTCH1 target
genes. In addition, the NOTCH1 mutation
is correlated with a more advanced clin-
ical stage at diagnosis, a shorter survival,
and an increased frequency of transfor-
mation into diffuse large B cell lymphoma
(DLBCL). All of the MYD88 mutations,ell 20, July 12, 2011 ª2011 Elsevier Inc. 5
